BTIG Research downgraded Omnicell from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $44.00 → $57.00 | Buy → Neutral | BofA Securities |
| 8/2/2024 | $26.00 → $39.00 | Underweight → Equal Weight | Barclays |
| 1/3/2024 | $33.00 | Underweight | Barclays |
| 11/3/2023 | $39.00 → $28.00 | Underweight → Equal Weight | Wells Fargo |
| 11/3/2023 | Buy → Neutral | BTIG Research | |
| 11/3/2023 | $70.00 → $39.00 | Neutral → Overweight | Piper Sandler |
| 10/11/2023 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 9/26/2023 | $56.00 → $39.00 | Underweight | Wells Fargo |
The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:OMCL) with a Buy and maintains $38 price target.
Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:OMCL) with a Buy and maintains $38 price target.
The table below summarizes Omnicell's second quarter and full year 2024 guidance outlined above. Q2 2024 2024 Bookings Not provided $750 million - $875 million Total Revenues $250 million - $260 million $1.045 billion - $1.120 billion Product Revenues $140 million - $145 million $605 million - $650 million Service Revenues $110 million - $115 million $440 million - $470 million Technical Services Revenues Not
Omnicell delivers solid third quarter financial results Total revenues of $282 million GAAP net income per diluted share of $0.19 Non-GAAP net income per diluted share of $0.56 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its third quarter ended September 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased to deliver another consecutive quarter of solid financial performance, with results within or exceeding each of ou
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, will release its financial results for the third quarter 2024, before market open on Wednesday, October 30, 2024. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 6944646. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About Omnice
Results exceed previously issued second quarter guidance across all metrics Total revenues of $277 million GAAP net income per diluted share of $0.08 Non-GAAP net income per diluted share of $0.51 Raises 2024 non-GAAP EBITDA and non-GAAP earnings per share guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy care delivery model, today announced results for its second quarter ended June 30, 2024. Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell, said, "We are pleased with the second quarter results that we announced today, which exceeded our previously issue
8-K - OMNICELL, INC. (0000926326) (Filer)
10-Q - OMNICELL, INC. (0000926326) (Filer)
8-K - OMNICELL, INC. (0000926326) (Filer)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
SC 13G/A - OMNICELL, INC. (0000926326) (Subject)
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
4 - OMNICELL, INC. (0000926326) (Issuer)
BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously
Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously
Barclays initiated coverage of Omnicell with a rating of Underweight and set a new price target of $33.00
Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 2:00 p.m. ET. Live and archived webcasts of the presentation will be available through the Omnicell website at: https://ir.omnicell.com/events-and-presentations/ About Omnicell Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helpin
Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell") today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The sale of the notes is expected to close on November 22, 2024, subject to cu
Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell") today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The notes will